History of the use of HPV testing in cervical screening and in the management of abnormal cervical screening results

Journal of Clinical Virology

Volumn 45, Issue SUPPL. 1, 2009, Pages

  Cox, J Thomas ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cotesting; HPV mRNA; Human papillomavirus (HPV); hybrid capture; Invader HPV; p16; Papanicolaou (Pap) test; polymerase chain reaction (PCR); testing

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; MESSENGER RNA; WART VIRUS VACCINE;

ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE; CANCER RISK; CANCER SCREENING; CANCER THERAPY; CARCINOGENESIS; CLINICAL STUDY; COLPOSCOPY; CYTOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; FOLLOW UP; HIGH RISK POPULATION; HUMAN; ONCOGENE; PAPANICOLAOU TEST; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; REPEAT PROCEDURE; REVIEW; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VIRUS DETECTION; WART VIRUS;

FEMALE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 67949091327     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6532(09)70002-2     Document Type: Review

References (59)

1. Dürst M., Gissmann L., Ikenberg H., and zur Hausen H. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA 80 (1983) 3812-3815
2. Boshart M., Gissmann L., Ikenberg H., Kleinheinz A., Scheurlen W., and zur Hausen H. A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J 3 (1984) 1151-1157
3. Meisels A., and Fortein R. Condylomatous lesions of the cervix and vagina. I. Cytologic patterns. Acta Cytol 20 (1976) 505-509
4. Schwarz E., Freese U.K., Gissmann L., Mayer W., Roggenbuck B., Stremlau A., and zur Hausen H. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature 314 (1985) 111-114
5. Zhou J., Sun X.Y., Davies H., Crawford L., Park D., and Frazer I.H. Definition of linear antigenic regions of the HPV16 L1 capsid protein using synthetic virion-like particles. Virology 189 (1992) 592-599
6. Tidy J.A., Mason W.P., and Farrell P.J. A new and sensitive method of screening for human papillomavirus infection. Obstet Gynecol 74 (1989) 410-414
7. Reid R., Greenberg M.D., Lorincz A., Jenson A.B., Laverty C.R., Husain M., et al. Should cervical cytologic testing be augmented by cervicography or human papillomavirus deoxyribonucleic acid detection. Am J Obstet Gynecol 164 (1991) 1461-1469
8. Cox J.T., Schiffman M.H., Winzelberg A.J., and Patterson J.M. An evaluation of human papillomavirus testing as part of referral to colposcopy clinics. Obstet Gynecol 80 (1992) 389-395
9. National Cancer Institute Workshop. Thea 1988 Bethesda System for reporting cervical/vaginal cytologic diagnosis. J Am Med Assoc 262 (1989) 931-934
10. Cox J.T. Clinical role of HPV testing. Obstet Gynecol Clin North Am 23 (1996) 811-851
11. Kinney W.K., Manos M.M., Hurley L.B., and Ransley J.E. Where's the high-grade cervical neoplasia? The importance of the minimally abnormal Papanicolaou diagnosis. Obstet Gynecol 91 (1998) 973-976
12. Cox J.T. Editorial. Evaluating the role of HPV testing for women with equivocal Papanicolaou test findings. J Am Med Assoc 281 (1999) 1645-1647
13. Wright T.C., Sun X.W., and Koulos J. Comparison of management algorithms for the evaluation of women with low-grade cytologic abnormalities. Obstet Gynecol 85 (1995) 202-210
14. Cox J.T., Lorincz A.T., Schiffman M.H., Sherman M.E., Cullen A., and Kurman R.J. Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 172 (1995) 946-954
15. Wright T.C., Lorincz A.T., Ferris D.G., et al. Reflex human papillomavirus deoxyribonucleic acid testing in women with abnormal Pap smears. Am J Obstet Gynecol 178 (1998) 962-966
16. Schiffman M., and Adrianza M.E. ASCUS LSIL Triage Study. Design, methods and characteristics of trial participants. Acta Cytol 44 (2000) 726-742
17. Solomon D., Schiffman M.H., Tarone B., and for the ALTS Group. Comparison of HPV testing, repeat cytology, and immediate colposcopy in ASCUS triage: baseline results from a randomized trial. J Natl Cancer Inst 93 (2001) 293-299
18. The ASCUS LSIL Triage Study (ALTS)* Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 188 (2003) 1383-1392
19. Wright Jr. T.C., Cox J.T., Massad L.S., Twiggs L.B., and Wilkinson E.J. 2001 ASCCP-Sponsored Consensus Conference. 2001 Consensus guidelines for the management of women with cervical cytological abnormalities. JAmMed Assoc 287 (2002) 2120-2129
20. Manos M.M., Kinney W.K., Hurley L.B., et al. Identifying women with cervical neoplasia: using human papillomavirus testing for equivocal Papanicolaou results. J Am Med Assoc 281 (1999) 1605-1610
21. Koutsky L., and for the ALTS Group. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. J Natl Cancer Inst 92 (2000) 397-402
22. ASCUS LSIL Triage Study (ALTS) Group. A randomized trial on the management of LSIL cytology interpretations. Am J Obstet Gynecol 188 (2003) 1393-1400
23. Wright Jr. T.C., Massad L.S., Dunton C.J., Spitzer M., Wilkinson E.J., and Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis 11 4 (2007) 201-222
24. Wright Jr. T.C., Massad L.S., Dunton C.J., Spitzer M., Wilkinson E.J., and Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 197 (2007) 346-355
25. Arbyn M., Buntinx F., Van Ranst M., Paraskevaidis E., Martin-Hirsh P., and Dillner J. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 96 (2004) 280-293
26. Kim J.J., Wright T.C., and Goldie S.J. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA 287 (2002) 2382-2390
27. Cox J.T., Wilkinson E., Lonky N., Waxman A., Tosh R., and Tedeschi C. ASSCP Practice Guideline: Management Guidelines for follow-up of atypical squamous cells of undetermined significance (ASCUS). J Low Genit Tract Dis 4 (2000) 99-113
28. Cox J.T., Massad L.S., Lonky N., Tosh R., Waxman A., and Wilkinson E. ASSCP Practice Guideline: Management Guidelines for follow-up of low grade squamous intraepithelial lesion (LSIL). J Low Gen Tract Dis 4 (2000) 83-92
29. Cox J.T. Management of precursor lesions of cervical carcinoma: history, host defense, and a survey of modalities. In: Lonky N. (Ed). Preventing mortality and morbidity from cervical cancer, OB/GYN Clinics of North America 29 (2002), W.B. Saunders 751-785
30. Cox J.T., Schiffman M., Solomon D., and ASCUS LSIL Triage Study Group. Prospective follow-up suggest similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol 188 (2002) 1406-1412
31. Guido R., Schiffman M., Solomon D., Burke L., and ASCUS LSIL Triage Study Group. Postcolposcopy management strategies for patients referred with low-grade squamous intraepithelial lesions or human papillomavirus DNA-positive atypical squamous cells of undetermined significance: a two-year prospective study. Am J Obstet Gynecol 188 (2003) 1401-1405
32. Paraskevaidis E., Koliopoulos G., Alamanos Y., Malamou-Mitsi V., Lolis E.D., and Kitchener H.C. Human papillomavirus testing and the outcome of treatment for cervical intraepithelial neoplasia. Obstet Gynecol 98 (2001) 833-836
33. Nobbenhuis M.A., Meijer C.J., van den Brule A.J., Rozendaal L., Voorhorst F.J., Risse E.K., et al. Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. Br J Cancer 84 (2001) 796-801
34. Arbyn M., Paraskevaidis E., Martin-Hirsch P., Prendiville W., and Dillner J. Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol Oncol 99 3 Suppl 1 (2005) S7-11
35. Kreimer A.R., Guido R.S., Solomon D., Schiffman M., Wacholder S., Jeronimo J., et al. Human papillomavirus testing following loop electrosurgical excision procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease. Cancer Epidemiol Biomarkers Prev 15 (2006) 908-914
36. Meijer C.J., van den Brule A.J., Snijders P.J., Helmerhorst T., Kenemans P., and Walboomers J.M. Detection of human papillomavirus in cervical scrapes by the polymerase chain reaction in relation to cytology: possible implications for cervical cancer screening. IARC Sci Publ 119 (1992) 271-281
37. Sherman M.E., Lorinzc A.T., Scott D.R., Wacholder S., Castle P.R., Glass A.G., et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: A ten year cohort analysis. J Natl Cancer Inst 95 (2003) 46-52
38. Cuzick J., Szarewski A., Terry G., Ho L., Hanby A., Maddox P., et al. Human papillomavirus testing in primary cervical screening. Lancet 345 (1995) 1533-1536
39. Cuzick J., Beverley E., Ho L., Terry G., Sapper H., Mielzynska I., et al. HPV testing in primary screening of older women. Br J Cancer 81 (1999) 554-558
40. Mayrand M.H., Duarte-Franco E., Rodrigues I., Walter S.D., Hanley J., Ferenczy A., et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 357 (2007) 1579-1588
41. Cuzick J., Szarewski A., Mesher D., Cadman L., Austin J., Perryman K., et al. Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology Results from the Hammersmith study. Int J Cancer 122 (2008) 2294-2300
42. Dillner J., Rebolj M., Birembaut P., Petry K., Szarewski A., Munk C., et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ (2009)
43. Cuzick J., Arbyn M., Sankaranarayanan R., Tsu V., Ronco G., Mayrand M.H., et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 26 Suppl 10 (2008) K29-K41
44. Naucler P., Ryd W., Törnberg S., Strand A., Wadell G., Elfgren K., et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 101 (2009) 88-99
45. Khan M.J., Castle P.E., Lorincz A.T., Wacholder S., Sherman M., Scott D.R., et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 97 (2005) 1072-1079
46. Castle P.E., Solomon D., Schiffman M., Wheeler C.M., and for the ALTS Group. Human papillomavirus type 16 infections and 2 year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst 97 (2005) 1066-1071
47. Ginocchio C.C., Barth D., and Zhang F. Comparison of the Third Wave Invader human papillomavirus (HPV) assay and the Digene HPV Hybrid Capture 2 assay for detection of high-risk HPV DNA. J Clin Microbiol 46 (2008) 1641-1646
48. Wong A.K., Chan R.C., Nichols W.S., and Bose S. Invader human papillomavirus (HPV) type 16 and 18 assays as adjuncts to HPV screening of cervical Papanicolaou smears with atypical squamous cells of undetermined significance. Cancer 115 (2009) 823-832
49. Cuschieri K., and Wentzensen N. Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 17 (2008) 2536-2545
50. Castle P.E., Dockter J., Giachetti C., Garcia F.A., McCormick M.K., Mitchell A.L., et al. A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical precancer and cancer. Clin Cancer Res 13 (2007) 2599-2605
51. Dixon E.P., King L.M., Adams M.D., Grønn P., Murphy P.G., Brown C.A., et al. Isolation of RNA from residual BD SurePath liquid-based cytology specimens and detection of HPV E6/E7 mRNA using the PreTectt HPV-Proofer assay. J Virol Methods 154 (2008) 220-222
52. Dockter J., Schroder A., Hill C., Guzenski L., Monsonego J., and Giachetti C. Clinical performance of the APTIMA® HPV Assay for the detection of high-risk HPV and high-grade cervical lesions. J Clin Virol 45 Suppl 1 (2009) S55-S61
53. Villa L.L. Assessment of new technologies for cervical cancer screening. Lancet Oncol 9 (2008) 910-911
54. Horn L.C., Reichert A., Oster A., et al. Immunostaining for p16INK4a used as a conjunctive tool improves interobserver agreement of the histologic diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol 32 (2008) 502-512
55. Carozzi F., Confortini M., Dalla Palma P., et al. Use of p16-INK4A overexpression to increase the specifi city of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 9 (2008) 937-945
56. Datta S.D., Koutsky L.A., Ratelle S., Unger E.R., Shlay J., McClain T., et al. Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003 2005. Ann Intern Med 148 (2008) I32
57. Castle P.E., Fetterman B., Poitras N., Lorey T., Shaber R., and Kinney W. Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting. Obstet Gynecol 113 (2009) 595-600
58. Goldhaber-Fiebert J.D., Stout N.K., Salomon J.A., Kuntz K.M., and Goldie S.J. Costeffectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst 100 (2008) 308-320
59. Crum C.P., Abbott D.W., and Quade B.J. Cervical cancer screening: from the Papanicolaou smear to the vaccine era. J Clin Oncol 21 (2003) 224s-230s